Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2018 on file Net Income-$635.83K-$635.83KderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$637,875N/M Operating Cash Flowderived-$568,370N/M ended Dec 31, 2019 · filed Mar 30, 2020 · 90 d after period end